CBD-OS

Phase 3Small molecule

CBD-OS is one of 3 small molecule programs targeting Developmental and Epileptic Encephalopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Developmental and Epileptic EncephalopathyNot yet recruiting

Focal SeizuresRecruiting

Developmental and Epileptic EncephalopathyPhase 3

Not yet recruiting

Focal SeizuresPhase 1

Recruiting

Competition

Competitive Landscape

2 competitors in Developmental and Epileptic Encephalopathy

#DrugCompanyPhaseTrials

Epidiolex

CBD-OS

1 3

LP352

LLongboard Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Focal Seizures

NCT07233239

Q3 2029

Phase 3Not yet recruiting

Developmental and Epileptic Encephalopathy

NCT07723976

Clinical

Trials by Indication[1]

Focal Seizures1 trial

A Phase 1b, Multicenter, Open-Label, Single-arm Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) in Participants Aged 12 to 75 Years for the Treatment of Focal-Onset Seizures

Recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 1·NCT07233239·100 enrolled

Developmental and Epileptic Encephalopathy1 trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Cannabidiol Oral Solution (CBD-OS, JZP926-OS) in Participants Aged 1 Year and Older With Developmental and Epileptic Encephalopathy (DEE)

Not yet recruiting· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT07723976·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CBD-OS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CBD-OS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CBD-OS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Jazz Pharmaceuticals

CBD-OS

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Trials by Indication[1]

Focal Seizures1 trial

Developmental and Epileptic Encephalopathy1 trial

References

Drug Info

Quick Facts

Related News